Corvia Medical, a Tewksbury, MA-based company dedicated to transforming the treatment of heart failure (HF), raised USD54M in funding.
Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and Edwards Lifesciences.
The company intends to use the funds to support a confirmatory trial that builds on the extensive data and progressive learnings from the REDUCE LAP-HF II clinical trial of the Corvia Atrial Shunt in heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction.
Led by CEO George Fazio, Corvia Medical is dedicate to advancing a treatment of heart failure through novel transcatheter cardiovascular devices. The Corvia Atrial Shunt, which was granted Breakthrough Device designation by the FDA in 2019, is designed to reduce elevated left atrial pressure (LAP), the primary contributor of HF symptoms in HFpEF patients. The shunt is placed via catheter between the left and right atria, forming a passage that allows blood to flow from the high pressure left atrium to the lower pressure right atrium, with the aim of reducing HF symptoms and events and improving quality of life.
FinSMEs
13/06/2022